Pfizer has issued a voluntary recall of certain lots of penicillin G benzathine injectable suspension (Bicillin L-A) due to particulates identified during visual inspection. Health care organizations should confirm whether any of their current stock of Bicillin L-A has been affected by the recall. The U.S. Centers for Disease Control and Prevention (U.S. CDC) has provided information on priority actions to take following the recall. The Maine Center for Disease Control and Prevention (Maine CDC) is currently monitoring the situation and recommends that the remaining stock of Bicillin L-A be preserved for treatment of syphilis in pregnant persons.